About half way through my term of service with AmeriCorps, I have written lesson plans for our new college counseling curriculum and I am building our volunteer managment program from the ground up. I can imagine these activities are similar to the process needed to write a communication plan for a health behavior intervention and then work to train the community health workers that would education the community about that health intervention, but I can not be sure. I have amazed myself with how much my thought process has changed in such a short period of time. My first concern has become what is probable rather than what is possible for organizational sustainability. Where I used to focus on only the program I worked on, I now have to make tough decisions about our limitations.
I know that professional and personal development has improved as a result of my daring to think differently about my potential and my role in a nonprofit.
GlaxoSmithKline is daring to think different(ly) as well by expanding access to medicines for neglected diseases in some of the least developed countries. The corporation also plans to open access to their medical technologies in development to other sciences to expand research on treatments for neglected diseases. Whether out of a moral obligation or the pursuit of a financial opportunity, this unprecedented level of access has the potential to help countless numbers of patients. Furthermore, this is the first time that I have heard of a private sector company acting on the reality that universal access to treatment while necessary is not sufficient for eradication of certain diseases.
There needs to be a simultaneous focus on expanding access and improving health systems to build capacity for increased usage. Even then, it is unlikely actions GSK takes now will become the only road for eradication of diseases. As a corporate social responsibility venture, GSK may reap the benefit of positive public relations and somewhat increased profits from the now possible sales. However, it is difficult to tell how many countries will be able to afford medicines even at these discounted profits. The real benefit for developing countries lies in the potential for increased research for neglected diseases that affect developing countries most. OneWorld Health is the only major nonprofit pharmaceutical company that focuses on research and development of treatments for neglected diseases; having a major Big Pharma company devote more time and resources might be enough to tip the balance for some substantive development.
Tonight I opened Google Reader for the first time in over a month. I hoped that the feed reader had not exploded with the over 100 feeds I subscribe to. The sight of the 1000+ articles sitting there awaiting my perusal inspired me to do something that I don’t do often enough: say no. I have now dumped half of these feeds. It simply was too overwhelming and frankly ridiculous of me to think that I could consume that much information on a daily basis. It is an ongoing negative habit of mine: take on more and more responsibility until I drive myself crazy.
I miss reading and talking about public health now that my brain is constantly occupied with nonprofit management and education due to AmeriCorps. I love what I do everyday but I know that the issues that I really want to explore are in public health and not education. I did not realize how difficult it would be to devote myself to both disciplines this year.
After reading on change.org about the amazing strides that Frontline: SMS has made in advancing mobile health in Malawi, I knew that I wanted to jump back in. Reading and writing about public health will bring back some of the excitement I felt about going to grad school. I have gotten in to Emory and Johns Hopkins so I definitely need to step up my game so that I will be ready next fall.